Cell Source, Inc. (CLCS)
Stock Price:
$1.10 USD
-0.27 (-19.71%)
Updated Aug 10, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
30.06M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-3.83M |
| Shares Out |
27.33M |
| EPS (ttm) |
-0.16 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 10, 2020 |
| Last Price |
$1.10 |
| Previous Close |
$1.37 |
| Change ($) |
-0.27 |
| Change (%) |
-19.71% |
| Day's Open |
1.39 |
| Day's Range |
1.10 - 1.50 |
| Day's Volume |
11,727 |
| 52-Week Range |
0.41 - 1.56 |
More Stats
| Market Cap |
30.06M |
| Enterprise Value |
33.10M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
27.33M |
| Float |
18.00M |
| EPS (basic) |
-0.16 |
| EPS (diluted) |
-0.16 |
| FCF / Share |
-0.10 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
0.64 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
n/a |
| Revenue |
n/a |
| Operating Income |
-3.37M |
| Net Income |
-3.83M |
| Free Cash Flow |
-2.80M |
| Net Cash |
-3.04M |
| Net Cash / Share |
-0.11 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-2,208.97% |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|
| Revenue | - | - | - | - | - | - | - |
| Operating Income | -3.81 | -2.01 | -2.29 | -2.32 | -2.32 | -4.05 | -1.46 |
| Net Income | -4.48 | -2.12 | -3.08 | -0.97 | -2.50 | -4.06 | -1.78 |
| Shares Outstanding | 28.33 | 27.55 | 26.77 | 26.19 | 25.72 | 22.19 | 13.17 |
| Earnings Per Share | -0.18 | -0.09 | -0.12 | -0.04 | -0.10 | -0.18 | -0.14 |
| Operating Cash Flow | -2.59 | -2.00 | -2.29 | -1.49 | -2.00 | -3.12 | -0.89 |
| Capital Expenditures | - | - | - | - | - | - | - |
| Free Cash Flow | -2.59 | -2.00 | -2.29 | -1.49 | -2.00 | -3.12 | -0.89 |
| Cash & Equivalents | 0.03 | 0.02 | 0.37 | 0.00 | 0.01 | 0.02 | 0.03 |
| Total Debt | 2.60 | 2.67 | 2.32 | 3.09 | 1.11 | 0.10 | - |
| Net Cash / Debt | -2.57 | -2.65 | -1.95 | -3.08 | -1.11 | -0.08 | 0.03 |
| Assets | 0.11 | 0.07 | 0.53 | 0.21 | 0.21 | 0.12 | 0.09 |
| Liabilities | 5.86 | 4.99 | 5.09 | 6.45 | 5.97 | 3.91 | 0.79 |
| Book Value | -5.74 | -4.92 | -4.56 | -6.24 | -5.76 | -3.78 | -0.70 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Cell Source, Inc. |
| Country |
United States |
| Employees |
1 |
| CEO |
Itamar Shimrat |
Stock Information
| Ticker Symbol |
CLCS |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: CLCS |
Description
Cell Source, Inc., a cell therapy company, focuses on developing and commercializing immunotherapy medicines in Israel. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, such as treatment of lymphoma, leukemia, and multiple myeloma; and facilitating the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. The company was founded in 2011 and is headquartered in New York, New York.